Polypharmacy, Treatment Response, and Adverse Events in RA Polypharmacy, Treatment Response, and Adverse Events in RA

The use of multiple medications may negatively impact rheumatoid arthritis treatment outcomes and increase the risk for serious adverse events.Rheumatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Related Links:

Activation of TGR5 alleviates inflammation in rheumatoid arthritis peripheral blood mononuclear cells and in mice with collagen II‑induced arthritis. Mol Med Rep. 2019 Sep 26;: Authors: Li ZY, Zhou JJ, Luo CL, Zhang LM Abstract Rheumatoid arthritis (RA) is characterized by chronic inflammatory synovitis resulting in progressive joint destruction. Persistent synovial inflammation is induced by activation of various inflammatory cells. G‑protein‑coupled bile acid receptor 1 (TGR5) is a G‑protein‑coupled receptor activated by various bile acids, which has been reported to act as a key adaptor ...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Authors: Tada M, Inui K, Okano T, Mamoto K, Koike T, Nakamura H Abstract The general disease activity of patients with rheumatoid arthritis (RA) is well controlled by disease-modifying antirheumatic drugs, but local inflammation often remains in a few small joints. Electroporation, making small pores in cell membranes, has proven useful for drug delivery. The safety of a combination therapy of methotrexate (MTX) and electroporation for local joint inflammation in RA was investigated in a prospective, randomized, double-blind, placebo-controlled, exploratory study (UMIN000016606). The patients were randomly allocate...
Source: Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders - Category: Orthopaedics Tags: Clin Med Insights Arthritis Musculoskelet Disord Source Type: research
ConclusionIn search of new drugs, phytochemicals like flavonoids, glycosides, alkaloids, lignans &terpenes offer a wide canvas to develop into valuable forthcoming medicaments.Graphical AbstractPhytochemicals inhibiting matrix metalloproteinase regulating tissue degradation in inflammatory disorders, malignancies and fibrosis
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
Authors: Rajabinejad M, Salari F, Gorgin Karaji A, Rezaiemanesh A Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of the immature myeloid cells that are derived from the myeloid progenitors with immunosuppressive functions. MDSCs are accumulated in the inflammatory sites during some autoimmune disorders, such as rheumatoid arthritis (RA) and can be an important factor in the pathogenesis of these diseases. Some research has shown the anti-inflammatory role of MDSCs during the RA progression and supports the hypothesis that MDSCs can be a potential treatment option for autoimmunity with t...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
In patients with early rheumatoid arthritis, using ultrasound to guide treatment...Read more on AuntMinnie.comRelated Reading: SNMMI: Technetium radiotracer tracks rheumatoid arthritis C-11-based PET tracer could benefit arthritis patients Novel PET tracer could help assess arthritis Ultrasound helps fine-tune management of arthritis
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
China's Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira (adalimumab), paving the way for the first such biosimilar to enter the world's second-largest drug market.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
Authors: El Jammal T, Gerfaud-Valentin M, Sève P, Jamilloux Y Abstract In the past ten years, the better understanding of the pathophysiological mechanisms underlying inflammatory and autoimmune diseases has led to the emergence of many targeted therapies. Among them, the Janus kinase inhibitors are acting upstream in the inflammatory cascade of several key cytokines in disorders such as rheumatoid arthritis, ulcerative colitis or psoriasis. At the moment, these three diseases represent the only indications validated by the FDA and the EMA of the use of JAK inhibitors apart from hematology. Preclinical data ...
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
CONCLUSIONS: According to the proposed algorithm, ANA IIF+MFI- subjects should be screened by an alternative solid-phase assay such as line-immunoassay or ELISA. PMID: 31694754 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
CONCLUSIONS: No association between ApoB/apoA1 ratio and CVE was found at the baseline visit of patients with RA from the CARMA study. PMID: 31694752 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
CONCLUSIONS: These results indicated that FER1L4 regulates RA via targeting NLRC5 potentially. Therefore, this study may provide a candidate therapeutic target for RA. PMID: 31694750 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
More News: Arthritis | Health | Rheumatoid Arthritis | Rheumatology